Featured 13F manager
FARALLON CAPITAL MANAGEMENT, L.L.C.
San Francisco, CA 87 13Fs · since 2021 Q3
- $21.7B
- 82 Positions
- 2026 Q2
- +23.6% QoQ
- Top 5 29.9%
Portfolio
top 5 29.9% · top 10 44.0%
- RVMD - Revolution Medicines 11.7%
- EA - Electronic Arts 7.5%
- BBIO - Bridgebio Pharma 3.7%
- PTGX - Protagonist Therapeut… 3.6%
- EXEL - Exelixis 3.4%
- LQDA - Liquidia 3.1%
- AMZN - Amazon 2.9%
- LNTH - Lantheus 2.9%
- NTRA - Natera 2.8%
- UNH - Unitedhealth 2.4%
- TMO - Thermo Fisher 2.4%
- ROIV - Roivant Sciences 2.3%
- Other 51.3%
AUM over time
Latest book
| RVMD - Revolution Medicines | 11.71% | Reduce −0.4% | $2.5B | 13,550,796 | $187.28 | $2.5B | −54,000 | +$1.2B |
| EA - Electronic Arts | 7.49% | New | $1.6B | 7,919,500 | $205.04 | $1.6B | +7,919,500 | +$1.6B |
| BBIO - Bridgebio Pharma | 3.69% | Add +14.7% | $800M | 10,743,063 | $74.48 | $800M | +1,377,600 | +$105M |
| PTGX - Protagonist Therapeut… | 3.59% | Hold | $778M | 6,348,906 | $122.58 | $778M | — | — |
| EXEL - Exelixis | 3.38% | Add +2.7% | $733M | 13,468,010 | $54.41 | $733M | +357,000 | +$170M |
| LQDA - Liquidia | 3.08% | Reduce −3.4% | $667M | 8,365,038 | $79.73 | $667M | −291,000 | +$340M |
| AMZN - Amazon | 2.90% | Reduce −37.6% | $628M | 2,632,994 | $238.34 | $628M | −1,585,400 | −$251M |
| LNTH - Lantheus | 2.86% | Hold | $619M | 5,583,479 | $110.94 | $619M | — | — |
| NTRA - Natera | 2.78% | Reduce −30.8% | $602M | 2,218,366 | $271.45 | $602M | −989,000 | −$39M |
| UNH - Unitedhealth | 2.44% | Reduce −30.3% | $528M | 1,270,532 | $415.63 | $528M | −551,174 | +$35M |
| TMO - Thermo Fisher | 2.43% | Add +19.0% | $526M | 1,049,185 | $501.36 | $526M | +167,700 | +$93M |
| ROIV - Roivant Sciences | 2.34% | Add +47.9% | $506M | 14,309,000 | $35.39 | $506M | +4,634,000 | +$238M |
| AON - Aon | 2.12% | Reduce −45.0% | $459M | 1,382,562 | $331.69 | $459M | −1,130,076 | −$352M |
| BSX - Boston Scientific | 2.07% | Add +40.8% | $449M | 10,521,184 | $42.68 | $449M | +3,050,500 | −$20M |
| AVGO - Broadcom | 2.01% | Reduce −35.3% | $435M | 1,151,800 | $377.75 | $435M | −627,700 | −$116M |
| MSFT - Microsoft | 1.92% | Reduce −52.5% | $415M | 1,112,863 | $373.02 | $415M | −1,231,916 | −$453M |
| TNGX - Tango Therapeutics | 1.77% | Add +35.0% | $384M | 12,277,000 | $31.26 | $384M | +3,179,589 | +$193M |
| KKR - Kkr & | 1.74% | Reduce −11.8% | $378M | 4,118,300 | $91.78 | $378M | −553,500 | −$54M |
| SNPS - Synopsys | 1.71% | Reduce −31.6% | $370M | 829,600 | $446.07 | $370M | −383,700 | −$111M |
| BEAM - Beam Therapeutics | 1.62% | Add +1.0% | $351M | 10,236,396 | $34.32 | $351M | +101,700 | +$110M |
| CRNX - Crinetics Pharmaceuti… | 1.55% | Add +7.8% | $336M | 8,989,098 | $37.42 | $336M | +651,000 | +$34M |
| GRAL - Grail | 1.31% | Add +27.9% | $284M | 4,161,584 | $68.27 | $284M | +907,900 | +$116M |
| WAB - Wabtec | 1.11% | Reduce −44.4% | $241M | 894,503 | $269.60 | $241M | −714,900 | −$161M |
| IMVT - Immunovant | 1.03% | Add +275.5% | $224M | 5,805,000 | $38.53 | $224M | +4,259,000 | +$185M |
| TWST - Twist Bioscience | 1.01% | Add +49.6% | $220M | 2,136,400 | $102.88 | $220M | +708,750 | +$152M |
| AGIO - Agios Pharmaceuticals | 1.01% | Add +4.1% | $220M | 5,917,400 | $37.11 | $220M | +233,400 | +$27M |
| ARMK - Aramark | 0.95% | Reduce −40.9% | $206M | 3,625,731 | $56.90 | $206M | −2,509,700 | −$42M |
| BIDU - Baidu | 0.63% | Add +171.3% | $138M | 1,203,785 | $114.29 | $138M | +760,000 | +$88M |
| NVO - Novo-Nordisk A | 0.58% | Add +234.9% | $126M | 2,619,000 | $47.94 | $126M | +1,837,000 | +$97M |
| ACHC - Acadia Healthcare | 0.58% | Add +143.0% | $125M | 4,220,800 | $29.53 | $125M | +2,484,000 | +$84M |
| BTSG - Brightspring Health | 0.56% | Add +7.2% | $121M | 1,732,800 | $69.74 | $121M | +115,800 | +$52M |
| AZN - Astrazeneca | 0.50% | Add +153.4% | $109M | 574,000 | $189.62 | $109M | +347,501 | +$64M |
| JNJ - Johnson & | 0.48% | Add +175.7% | $104M | 408,000 | $253.97 | $104M | +260,000 | +$67M |
| Parabilis Medicines | 0.30% | New | $65M | 2,368,200 | $27.37 | $65M | +2,368,200 | +$65M |
| NVS - Novartis AG | 0.26% | New | $57M | 363,000 | $156.72 | $57M | +363,000 | +$57M |
| GH - Guardant Health | 0.22% | Add +3927.5% | $48M | 322,200 | $150.03 | $48M | +314,200 | +$48M |
| AVTX - Avalo Therapeutics | 0.21% | Add +172.7% | $46M | 2,498,000 | $18.48 | $46M | +1,582,000 | +$32M |
| JOYY - Joyy | 0.21% | Add +20.9% | $46M | 699,200 | $65.99 | $46M | +121,000 | +$12M |
| ASMB - Assembly Biosciences | 0.20% | Add +30.7% | $44M | 1,604,590 | $27.48 | $44M | +377,000 | +$10M |
| ENTA - Enanta Pharmaceuticals | 0.16% | Reduce −15.8% | $35M | 2,418,202 | $14.58 | $35M | −453,660 | −$1M |
| MAZE - Maze Therapeutics | 0.15% | Add +197.0% | $33M | 1,107,814 | $29.84 | $33M | +734,814 | +$22M |
| MRK - Merck & | 0.12% | Reduce −44.9% | $26M | 199,000 | $128.50 | $26M | −162,000 | −$18M |
| WRBY - Warby Parker | 0.12% | New | $25M | 828,000 | $30.34 | $25M | +828,000 | +$25M |
| Perceptive Cap | 0.11% | Hold | $24M | 2,250,000 | $10.88 | $24M | — | — |
| Kailera Therapeutics | 0.11% | New | $24M | 1,100,000 | $22.03 | $24M | +1,100,000 | +$24M |
| RIO - Rio Tinto | 0.08% | Add +241.0% | $17M | 183,475 | $94.93 | $17M | +129,675 | +$12M |
| AXTA - Axalta Coating | 0.08% | New | $16M | 478,000 | $34.22 | $16M | +478,000 | +$16M |
| ABVX - Abivax SA | 0.08% | Add +6000.0% | $16M | 122,000 | $133.26 | $16M | +120,000 | +$16M |
| VNET - Vnet | 0.07% | Add +219.6% | $16M | 1,992,000 | $8.04 | $16M | +1,368,653 | +$11M |
| NTES - Netease | 0.07% | Reduce −57.6% | $16M | 123,500 | $128.14 | $16M | −167,719 | −$17M |
| BIIB - Biogen | 0.07% | New | $15M | 71,000 | $216.06 | $15M | +71,000 | +$15M |
| TSHA - Taysha Gene | 0.07% | New | $15M | 2,250,000 | $6.81 | $15M | +2,250,000 | +$15M |
| Mobia Med | 0.07% | New | $15M | 1,128,557 | $13.40 | $15M | +1,128,557 | +$15M |
| NERV - Minerva Neurosciences | 0.06% | Hold | $13M | 2,365,000 | $5.55 | $13M | — | — |
| Alamar Biosciences | 0.06% | New | $13M | 462,900 | $27.09 | $13M | +462,900 | +$13M |
| Alvotech | 0.05% | Add +1332.2% | $11M | 2,859,675 | $3.69 | $11M | +2,660,000 | +$10M |
| BBNX - Beta Bionics | 0.04% | Reduce −83.5% | $9M | 595,000 | $15.67 | $9M | −3,012,920 | −$27M |
| Inflarx NV | 0.03% | New | $7M | 3,325,000 | $2.24 | $7M | +3,325,000 | +$7M |
| SMG - Scotts Miracle-Gro | 0.03% | New | $6M | 88,000 | $68.11 | $6M | +88,000 | +$6M |
| WAY - Waystar | 0.03% | New | $5M | 264,900 | $20.53 | $5M | +264,900 | +$5M |
| BC - Brunswick | 0.02% | New | $5M | 61,000 | $84.24 | $5M | +61,000 | +$5M |
| GNTX - Gentex | 0.02% | New | $5M | 199,000 | $25.27 | $5M | +199,000 | +$5M |
| IDXX - Idexx Labs | 0.02% | New | $5M | 9,000 | $526.44 | $5M | +9,000 | +$5M |
| PRME - Prime Medicine | 0.02% | Hold | $5M | 1,240,843 | $3.69 | $5M | — | — |
| CMC - Commercial Metals | 0.02% | New | $4M | 67,000 | $62.75 | $4M | +67,000 | +$4M |
| Jatt Ii | 0.02% | New | $3M | 300,000 | $11.36 | $3M | +300,000 | +$3M |
| Sagimet Biosciences | 0.01% | New | $3M | 415,000 | $7.73 | $3M | +415,000 | +$3M |
| SMC - Summit Midstream | 0.01% | Hold | $2M | 58,214 | $28.48 | $2M | — | — |
| TEVA - Teva Pharmaceutical | 0.01% | Reduce −88.7% | $1M | 40,000 | $33.88 | $1M | −314,000 | −$9M |
| RVMD - Revolution Medicines | 0.01% | Hold | $1M | 120,085 | $9.40 | $1M | — | — |
| COGT - Cogent Biosciences | 0.00% | Hold | $658K | 17,000 | $38.70 | $658K | — | — |
| ANNAW - Aleanna | 0.00% | Hold | $297K | 990,000 | $0.3000 | $297K | — | — |
| ANNA - Aleanna | 0.00% | Hold | $227K | 78,400 | $2.90 | $227K | — | — |
| WELL - Welltower | 0.00% | Reduce −99.5% | $227K | 1,000 | $226.97 | $227K | −199,000 | −$39M |
| SLDPW - Solid Power | 0.00% | Hold | $41K | 405,316 | $0.1022 | $41K | — | — |
| Blue Gold | 0.00% | Reduce −14.7% | $31K | 255,800 | $0.1200 | $31K | −44,200 | −$29K |
| PACB - Pacific Biosciences | 0.00% | Reduce −89.5% | $24K | 14,200 | $1.68 | $24K | −120,800 | −$154K |
| GERN - Geron | 0.00% | Reduce −66.5% | $18K | 14,400 | $1.28 | $18K | −28,600 | −$46K |
| Nvni | 0.00% | Hold | $18K | 375,000 | $0.0468 | $18K | — | — |
| CGC - Canopy Growth | 0.00% | Reduce −40.0% | $17K | 18,000 | $0.9500 | $17K | −12,000 | −$11K |
| RANI - Rani Therapeutics | 0.00% | Reduce −73.5% | $16K | 20,700 | $0.7604 | $16K | −57,300 | −$42K |
| BYND - Beyond Meat | 0.00% | Hold | $14K | 19,000 | $0.7500 | $14K | — | — |
| SCHW - Schwab Charles | 2.12% | Exit | $372M | 0 | $93.98 | $372M | −3,955,657 | −$372M |
| GOOG - Alphabet | 1.63% | Exit | $286M | 0 | $286.86 | $286M | −996,231 | −$286M |
| V - Visa | 1.45% | Exit | $254M | 0 | $302.24 | $254M | −840,710 | −$254M |
| DIS - Disney Walt | 1.32% | Exit | $231M | 0 | $96.38 | $231M | −2,401,591 | −$231M |
| MA - Mastercard | 1.24% | Exit | $217M | 0 | $499.66 | $217M | −435,071 | −$217M |
| MCK - Mckesson | 1.16% | Exit | $203M | 0 | $865.36 | $203M | −234,300 | −$203M |
| CNTA - Centessa Pharmaceutic… | 1.09% | Exit | $191M | 0 | $39.72 | $191M | −4,809,000 | −$191M |
| TYRA - Tyra Biosciences | 0.78% | Exit | $137M | 0 | $38.30 | $137M | −3,580,818 | −$137M |
| THC - Tenet Healthcare | 0.49% | Exit | $85M | 0 | $188.71 | $85M | −452,153 | −$85M |
| CAH - Cardinal Health | 0.44% | Exit | $78M | 0 | $211.31 | $78M | −368,000 | −$78M |
| PCVX - Vaxcyte | 0.42% | Exit | $73M | 0 | $58.11 | $73M | −1,261,000 | −$73M |
| DNTH - Dianthus Therapeutics | 0.40% | Exit | $70M | 0 | $83.92 | $70M | −836,000 | −$70M |
| CGON - Cg Oncology | 0.26% | Exit | $46M | 0 | $67.68 | $46M | −674,000 | −$46M |
| BITW - Bitwise 10 | 0.15% | Exit | $27M | 0 | $44.61 | $27M | −603,000 | −$27M |
| RPRX - Royalty Pharma | 0.13% | Exit | $24M | 0 | $47.97 | $24M | −493,000 | −$24M |
| CECO - Ceco Environmental | 0.08% | Exit | $14M | 0 | $59.58 | $14M | −234,000 | −$14M |
| GDS - Gds | 0.07% | Exit | $12M | 0 | $40.29 | $12M | −292,000 | −$12M |
| FORM - Formfactor | 0.03% | Exit | $5M | 0 | $96.99 | $5M | −56,500 | −$5M |
| MTZ - Mastec | 0.03% | Exit | $5M | 0 | $321.76 | $5M | −17,000 | −$5M |
| ENTG - Entegris | 0.03% | Exit | $5M | 0 | $117.23 | $5M | −45,500 | −$5M |
| C - Citigroup | 0.03% | Exit | $5M | 0 | $113.40 | $5M | −47,000 | −$5M |
| H - Hyatt Hotels | 0.03% | Exit | $5M | 0 | $143.78 | $5M | −36,000 | −$5M |
| WST - Western Alliance | 0.03% | Exit | $5M | 0 | $70.85 | $5M | −73,000 | −$5M |
| TKR - Timken | 0.03% | Exit | $5M | 0 | $100.57 | $5M | −51,000 | −$5M |
| FLEX - Flextronics | 0.03% | Exit | $5M | 0 | $65.46 | $5M | −78,000 | −$5M |
| SPGI - S&P | 0.03% | Exit | $5M | 0 | $425.33 | $5M | −12,000 | −$5M |
| LFUS - Littelfuse | 0.03% | Exit | $5M | 0 | $339.33 | $5M | −15,000 | −$5M |
| PIPR - Piper Sandler | 0.03% | Exit | $5M | 0 | $76.55 | $5M | −66,000 | −$5M |
| AIR - Aar | 0.03% | Exit | $5M | 0 | $109.46 | $5M | −46,000 | −$5M |
| GTX - Garrett Motion | 0.03% | Exit | $5M | 0 | $18.17 | $5M | −275,000 | −$5M |
| ROL - Rollins | 0.03% | Exit | $5M | 0 | $53.41 | $5M | −93,000 | −$5M |
| AFRM - Affirm | 0.03% | Exit | $5M | 0 | $45.82 | $5M | −108,000 | −$5M |
| Inter & | 0.03% | Exit | $5M | 0 | $7.96 | $5M | −614,500 | −$5M |
| CMI - Cummins | 0.03% | Exit | $5M | 0 | $538.00 | $5M | −9,000 | −$5M |
| FISV - Fiserv | 0.03% | Exit | $5M | 0 | $55.80 | $5M | −86,000 | −$5M |
| VRT - Vertiv | 0.03% | Exit | $5M | 0 | $250.58 | $5M | −19,000 | −$5M |
| AMKR - Amkor | 0.03% | Exit | $5M | 0 | $45.03 | $5M | −104,000 | −$5M |
| RNA - Atrium Therapeutics | 0.03% | Exit | $5M | 0 | $13.37 | $5M | −349,360 | −$5M |
| GFS - Globalfoundries | 0.03% | Exit | $5M | 0 | $44.48 | $5M | −105,000 | −$5M |
| MOH - Molina Healthcare | 0.03% | Exit | $5M | 0 | $133.31 | $5M | −35,000 | −$5M |
| IRD - Opus Genetics | 0.03% | Exit | $5M | 0 | $4.55 | $5M | −1,000,000 | −$5M |
| TENB - Tenable | 0.03% | Exit | $4M | 0 | $16.91 | $4M | −265,000 | −$4M |
| NOW - Servicenow | 0.02% | Exit | $4M | 0 | $104.56 | $4M | −41,000 | −$4M |
| MDGL - Madrigal Pharmaceutic… | 0.01% | Exit | $2M | 0 | $523.35 | $2M | −3,319 | −$2M |
| CAPR - Capricor Therapeutics | 0.01% | Exit | $1M | 0 | $30.39 | $1M | −41,000 | −$1M |
| ARWR - Arrowhead Pharmaceuti… | 0.01% | Exit | $991K | 0 | $62.72 | $991K | −15,800 | −$991K |
| Alkermes | — | Exit | $735K | 0 | $35.34 | $735K | −20,800 | −$735K |
| AXSM - Axsome Therapeutics | — | Exit | $676K | 0 | $169.00 | $676K | −4,000 | −$676K |
| ARQT - Arcutis Biotherapeuti… | — | Exit | $613K | 0 | $23.58 | $613K | −26,000 | −$613K |
| CELC - Celcuity | — | Exit | $457K | 0 | $114.25 | $457K | −4,000 | −$457K |
| LIVN - Livanova | — | Exit | $381K | 0 | $63.50 | $381K | −6,000 | −$381K |
| Terns Pharmaceuticals | — | Exit | $369K | 0 | $52.71 | $369K | −7,000 | −$369K |
| IONS - Ionis Pharmaceuticals | — | Exit | $360K | 0 | $75.00 | $360K | −4,800 | −$360K |
| TVTX - Travere Therapeutics | — | Exit | $357K | 0 | $29.75 | $357K | −12,000 | −$357K |
| GMED - Globus Med | — | Exit | $345K | 0 | $86.25 | $345K | −4,000 | −$345K |
| SRRK - Scholar Rock | — | Exit | $344K | 0 | $49.14 | $344K | −7,000 | −$344K |
| ONC - Beone Medicines | — | Exit | $327K | 0 | $297.27 | $327K | −1,100 | −$327K |
| WGS - Genedx | — | Exit | $321K | 0 | $64.20 | $321K | −5,000 | −$321K |
| COR - Cencora | — | Exit | $314K | 0 | $314.00 | $314K | −1,000 | −$314K |
| Nuvalent | — | Exit | $307K | 0 | $102.33 | $307K | −3,000 | −$307K |
| PGNY - Progyny | — | Exit | $306K | 0 | $17.00 | $306K | −18,000 | −$306K |
| STOK - Stoke Therapeutics | — | Exit | $293K | 0 | $32.56 | $293K | −9,000 | −$293K |
| ERAS - Erasca | — | Exit | $291K | 0 | $16.17 | $291K | −18,000 | −$291K |
| EHC - Encompass Health | — | Exit | $290K | 0 | $96.67 | $290K | −3,000 | −$290K |
| NKTR - Nektar Therapeutics | — | Exit | $288K | 0 | $72.00 | $288K | −4,000 | −$288K |
| GKOS - Glaukos | — | Exit | $280K | 0 | $107.69 | $280K | −2,600 | −$280K |
| MIRM - Mirum Pharmaceuticals | — | Exit | $277K | 0 | $92.33 | $277K | −3,000 | −$277K |
| SBRA - Sabra Health | — | Exit | $269K | 0 | $19.21 | $269K | −14,000 | −$269K |
| KRYS - Krystal Biotech | — | Exit | $258K | 0 | $258.00 | $258K | −1,000 | −$258K |
| OMER - Omeros | — | Exit | $243K | 0 | $10.57 | $243K | −23,000 | −$243K |
| ALMS - Alumis | — | Exit | $242K | 0 | $22.00 | $242K | −11,000 | −$242K |
| APLSUSD - Apellis Pharmaceutica… | — | Exit | $241K | 0 | $40.17 | $241K | −6,000 | −$241K |
| HQY - Healthequity | — | Exit | $234K | 0 | $83.57 | $234K | −2,800 | −$234K |
| SNDX - Syndax Pharmaceuticals | — | Exit | $234K | 0 | $23.40 | $234K | −10,000 | −$234K |
| AM6 - Amicus Therapeutic | — | Exit | $231K | 0 | $14.44 | $231K | −16,000 | −$231K |
| Uniqure NV | — | Exit | $229K | 0 | $16.36 | $229K | −14,000 | −$229K |
| BCRX - Biocryst Pharmaceutic… | — | Exit | $228K | 0 | $9.50 | $228K | −24,000 | −$228K |
| GRFS - Grifols S | — | Exit | $225K | 0 | $8.04 | $225K | −28,000 | −$225K |
| VCYT - Veracyte | — | Exit | $225K | 0 | $32.14 | $225K | −7,000 | −$225K |
| GEHC - GE HealthCare | — | Exit | $214K | 0 | $71.33 | $214K | −3,000 | −$214K |
| HIMS - Hims & | — | Exit | $208K | 0 | $20.80 | $208K | −10,000 | −$208K |
| BLTE - Belite Bio | — | Exit | $207K | 0 | $159.23 | $207K | −1,300 | −$207K |
| MMSI - Merit Med | — | Exit | $207K | 0 | $69.00 | $207K | −3,000 | −$207K |
| SUPN - Supernus Pharmaceutic… | — | Exit | $207K | 0 | $51.75 | $207K | −4,000 | −$207K |
| HR - Healthcare Rlty | — | Exit | $204K | 0 | $17.00 | $204K | −12,000 | −$204K |
| Urogen Pharma | — | Exit | $198K | 0 | $18.00 | $198K | −11,000 | −$198K |
| VIR - Vir Biotechnology | — | Exit | $197K | 0 | $8.95 | $197K | −22,000 | −$197K |
| PGEN - Precigen | — | Exit | $194K | 0 | $3.88 | $194K | −50,000 | −$194K |
| SDGR - Schrodinger | — | Exit | $193K | 0 | $11.35 | $193K | −17,000 | −$193K |
| DYN - Dyne Therapeutics | — | Exit | $181K | 0 | $18.10 | $181K | −10,000 | −$181K |
| NVAX - Novavax | — | Exit | $179K | 0 | $8.14 | $179K | −22,000 | −$179K |
| SLS - Sellas Life | — | Exit | $169K | 0 | $4.22 | $169K | −40,000 | −$169K |
| ADPT - Adaptive Biotechnolog… | — | Exit | $153K | 0 | $13.91 | $153K | −11,000 | −$153K |
| OCUL - Ocular Therapeutix | — | Exit | $152K | 0 | $8.44 | $152K | −18,000 | −$152K |
| NEO - Neogenomics | — | Exit | $141K | 0 | $7.42 | $141K | −19,000 | −$141K |
| ARDX - Ardelyx | — | Exit | $138K | 0 | $6.00 | $138K | −23,000 | −$138K |
| OSCR - Oscar Health | — | Exit | $126K | 0 | $11.45 | $126K | −11,000 | −$126K |
| NUVB - Nuvation Bio | — | Exit | $124K | 0 | $4.28 | $124K | −29,000 | −$124K |
| IOVA - Iovance Biotherapeuti… | — | Exit | $91K | 0 | $3.50 | $91K | −26,000 | −$91K |
| ALT - Altimmune | — | Exit | $85K | 0 | $3.08 | $85K | −27,600 | −$85K |
| CCCC - C4 Therapeutics | — | Exit | $74K | 0 | $2.64 | $74K | −28,000 | −$74K |
| TVRD - Tvardi Therapeutics | — | Exit | $68K | 0 | $3.17 | $68K | −21,438 | −$68K |
| IRWD - Ironwood Pharmaceutic… | — | Exit | $46K | 0 | $3.54 | $46K | −13,000 | −$46K |
| EVH - Evolent Health | — | Exit | $32K | 0 | $2.29 | $32K | −14,000 | −$32K |
Filings history
87 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 89 | $21.7B | +23.6% | 13F-HR | 8/14/2026 | 000090883426000432 |
| 2026 Q1 | 1 | $1.5B | — | NEW HOLDINGS | 8/14/2026 | 000090883426000434 |
| 2026 Q1 | 172 | $17.5B | −17.2% | 13F-HR | 5/15/2026 | 000090883426000240 |
| 2025 Q4 | 1 | $1B | — | NEW HOLDINGS | 8/14/2026 | 000090883426000433 |
| 2025 Q4 | 2 | $884M | — | NEW HOLDINGS | 5/15/2026 | 000090883426000241 |
| 2025 Q4 | 151 | $21.2B | −13.2% | 13F-HR | 2/17/2026 | 000090883426000087 |
| 2025 Q3 | 144 | $24.4B | — | RESTATEMENT | 2/17/2026 | 000090883426000086 |
| 2025 Q3 | 144 | $24.4B | +5.4% | 13F-HR | 11/14/2025 | 000090883425000353 |
| 2025 Q2 | 1 | $140M | — | NEW HOLDINGS | 2/17/2026 | 000090883426000085 |
| 2025 Q2 | 3 | $483M | — | NEW HOLDINGS | 11/14/2025 | 000090883425000352 |
| 2025 Q2 | 141 | $23.2B | +29.2% | 13F-HR | 8/14/2025 | 000090883425000248 |
| 2025 Q1 | 1 | $274M | — | NEW HOLDINGS | 2/17/2026 | 000090883426000084 |
| 2025 Q1 | 3 | $416M | — | NEW HOLDINGS | 11/14/2025 | 000090883425000351 |
| 2025 Q1 | 7 | $2.2B | — | NEW HOLDINGS | 8/14/2025 | 000090883425000247 |
| 2025 Q1 | 135 | $17.9B | −9.0% | 13F-HR | 5/15/2025 | 000090883425000177 |
| 2024 Q4 | 1 | $85M | — | NEW HOLDINGS | 2/17/2026 | 000090883426000083 |
| 2024 Q4 | 2 | $349M | — | NEW HOLDINGS | 11/14/2025 | 000090883425000350 |
| 2024 Q4 | 6 | $2.3B | — | NEW HOLDINGS | 8/14/2025 | 000090883425000246 |
| 2024 Q4 | 4 | $333M | — | NEW HOLDINGS | 5/15/2025 | 000090883425000180 |
| 2024 Q4 | 138 | $19.7B | −3.5% | 13F-HR | 2/14/2025 | 000090883425000081 |
| 2024 Q3 | 1 | $145M | — | NEW HOLDINGS | 11/14/2025 | 000090883425000349 |
| 2024 Q3 | 6 | $1.5B | — | NEW HOLDINGS | 8/14/2025 | 000090883425000243 |
| 2024 Q3 | 3 | $216M | — | NEW HOLDINGS | 5/15/2025 | 000090883425000179 |
| 2024 Q3 | 2 | $544M | — | NEW HOLDINGS | 2/14/2025 | 000090883425000080 |
| 2024 Q3 | 153 | $20.4B | −3.6% | 13F-HR | 11/14/2024 | 000090883424000307 |
| 2024 Q2 | 1 | $120M | — | NEW HOLDINGS | 11/14/2025 | 000090883425000348 |
| 2024 Q2 | 5 | $1.2B | — | NEW HOLDINGS | 8/14/2025 | 000090883425000245 |
| 2024 Q2 | 1 | $199M | — | NEW HOLDINGS | 5/15/2025 | 000090883425000178 |
| 2024 Q2 | 2 | $452M | — | NEW HOLDINGS | 2/14/2025 | 000090883425000079 |
| 2024 Q2 | 1 | $149M | — | NEW HOLDINGS | 11/14/2024 | 000090883424000324 |
| 2024 Q2 | 157 | $21.2B | −4.2% | 13F-HR | 8/14/2024 | 000090883424000200 |
| 2024 Q1 | 1 | $93M | — | NEW HOLDINGS | 11/14/2025 | 000090883425000347 |
| 2024 Q1 | 4 | $1.2B | — | NEW HOLDINGS | 8/14/2025 | 000090883425000244 |
| 2024 Q1 | 2 | $159M | — | NEW HOLDINGS | 2/14/2025 | 000090883425000078 |
| 2024 Q1 | 1 | $45M | — | NEW HOLDINGS | 8/14/2024 | 000090883424000202 |
| 2024 Q1 | 167 | $22.1B | — | RESTATEMENT | 5/24/2024 | 000090883424000159 |
| 2024 Q1 | 167 | $22.1B | +9.8% | 13F-HR | 5/15/2024 | 000090883424000135 |
| 2023 Q4 | 1 | $65M | — | NEW HOLDINGS | 11/14/2025 | 000090883425000346 |
| 2023 Q4 | 2 | $548M | — | NEW HOLDINGS | 8/14/2025 | 000090883425000250 |
| 2023 Q4 | 5 | $1.1B | — | NEW HOLDINGS | 5/15/2024 | 000090883424000141 |
| 2023 Q4 | 150 | $20.1B | +1.0% | 13F-HR | 2/14/2024 | 000090883424000070 |
| 2023 Q3 | 1 | $40M | — | NEW HOLDINGS | 11/14/2025 | 000090883425000345 |
| 2023 Q3 | 1 | $40M | — | NEW HOLDINGS | 5/15/2024 | 000090883424000138 |
| 2023 Q3 | 2 | $1.4B | — | NEW HOLDINGS | 2/14/2024 | 000090883424000077 |
| 2023 Q3 | 1 | $1.9B | — | NEW HOLDINGS | 2/12/2024 | 000090883424000049 |
| 2023 Q3 | 159 | $20B | +11.5% | 13F-HR | 11/14/2023 | 000090883423000150 |
| 2023 Q2 | 2 | $669M | — | NEW HOLDINGS | 2/14/2024 | 000090883424000076 |
| 2023 Q2 | 5 | $1.4B | — | NEW HOLDINGS | 11/14/2023 | 000090883423000157 |
| 2023 Q2 | 1 | $1.2B | — | NEW HOLDINGS | 10/26/2023 | 000090883423000134 |
| 2023 Q2 | 165 | $17.9B | +1.3% | 13F-HR | 8/14/2023 | 000090883423000109 |
| 2023 Q1 | 2 | $234M | — | NEW HOLDINGS | 2/14/2024 | 000090883424000075 |
| 2023 Q1 | 3 | $389M | — | NEW HOLDINGS | 11/14/2023 | 000090883423000156 |
| 2023 Q1 | 1 | $15M | — | NEW HOLDINGS | 8/14/2023 | 000090883423000110 |
| 2023 Q1 | 187 | $17.7B | +15.8% | 13F-HR | 5/15/2023 | 000117570723000127 |
| 2022 Q4 | 1 | $171M | — | NEW HOLDINGS | 2/14/2024 | 000090883424000074 |
| 2022 Q4 | 3 | $485M | — | NEW HOLDINGS | 11/14/2023 | 000090883423000155 |
| 2022 Q4 | 7 | $1B | — | NEW HOLDINGS | 5/15/2023 | 000117570723000136 |
| 2022 Q4 | 232 | $15.3B | −9.3% | 13F-HR | 2/14/2023 | 000117570723000051 |
| 2022 Q3 | 1 | $125M | — | NEW HOLDINGS | 2/14/2024 | 000090883424000073 |
| 2022 Q3 | 3 | $415M | — | NEW HOLDINGS | 11/14/2023 | 000090883423000154 |
| 2022 Q3 | 5 | $411M | — | NEW HOLDINGS | 5/15/2023 | 000117570723000135 |
| 2022 Q3 | 4 | $434M | — | NEW HOLDINGS | 2/14/2023 | 000090966123000005 |
| 2022 Q3 | 298 | $16.8B | +3.5% | 13F-HR | 11/14/2022 | 000156761922019851 |
| 2022 Q2 | 1 | $115M | — | NEW HOLDINGS | 2/14/2024 | 000090883424000081 |
| 2022 Q2 | 3 | $411M | — | NEW HOLDINGS | 11/14/2023 | 000090883423000153 |
| 2022 Q2 | 2 | $337M | — | NEW HOLDINGS | 5/15/2023 | 000117570723000134 |
| 2022 Q2 | 3 | $136M | — | NEW HOLDINGS | 2/14/2023 | 000090966123000003 |
| 2022 Q2 | 9 | $1.2B | — | NEW HOLDINGS | 11/14/2022 | 000156761922019862 |
| 2022 Q2 | 297 | $16.3B | −13.7% | 13F-HR | 8/15/2022 | 000156761922015953 |
| 2022 Q1 | 1 | $268M | — | NEW HOLDINGS | 11/14/2023 | 000090883423000152 |
| 2022 Q1 | 1 | $314M | — | NEW HOLDINGS | 5/15/2023 | 000117570723000133 |
| 2022 Q1 | 1 | $27M | — | NEW HOLDINGS | 2/14/2023 | 000090966123000002 |
| 2022 Q1 | 3 | $186M | — | NEW HOLDINGS | 11/14/2022 | 000156761922019864 |
| 2022 Q1 | 8 | $1.1B | — | NEW HOLDINGS | 8/15/2022 | 000156761922015972 |
| 2022 Q1 | 307 | $18.8B | +0.4% | 13F-HR | 5/16/2022 | 000156761922010736 |
| 2021 Q4 | 1 | $227M | — | NEW HOLDINGS | 5/15/2023 | 000117570723000132 |
| 2021 Q4 | 1 | $7M | — | NEW HOLDINGS | 11/14/2022 | 000156761922019852 |
| 2021 Q4 | 1 | $115M | — | NEW HOLDINGS | 8/15/2022 | 000156761922015968 |
| 2021 Q4 | 2 | $98M | — | NEW HOLDINGS | 5/19/2022 | 000156761922011257 |
| 2021 Q4 | 6 | $833M | — | NEW HOLDINGS | 5/16/2022 | 000156761922010757 |
| 2021 Q4 | 289 | $18.7B | −5.1% | 13F-HR | 2/14/2022 | 000156761922003965 |
| 2021 Q3 | 1 | $182M | — | NEW HOLDINGS | 5/15/2023 | 000117570723000131 |
| 2021 Q3 | 1 | $105M | — | NEW HOLDINGS | 8/15/2022 | 000156761922015964 |
| 2021 Q3 | 1 | $57M | — | NEW HOLDINGS | 5/19/2022 | 000156761922011256 |
| 2021 Q3 | 3 | $998M | — | NEW HOLDINGS | 5/16/2022 | 000156761922010753 |
| 2021 Q3 | 2 | $344M | — | NEW HOLDINGS | 2/14/2022 | 000156761922003981 |
| 2021 Q3 | 293 | $19.7B | — | 13F-HR | 11/15/2021 | 000095012321015168 |
About
FARALLON CAPITAL MANAGEMENT, L.L.C.
87 processed 13Fs · since 2021 Q3